Skip to main content
Erschienen in: Critical Care 1/2019

Open Access 01.12.2019 | Letter

Bronchoalveolar lavage fluid dilution in ICU patients: what we should know and what we should do

verfasst von: Yuetian Yu, Chunyan Liu, Zhongheng Zhang, Hui Shen, Yujie Li, Liangjing Lu, Yuan Gao

Erschienen in: Critical Care | Ausgabe 1/2019

Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s13054-018-2300-x) contains supplementary material, which is available to authorized users.
Yuetian Yu and Chunyan Liu contributed equally to this work.
Abkürzungen
BAL
Bronchoalveolar lavage
BALF
Bronchoalveolar lavage fluid
FEV1
Forced expiratory volume in the first second
ICU
Intensive care unit
The development of bronchoscopy and bronchoalveolar lavage (BAL) has led to an increase in their use in intensive care units (ICUs), where their applications for differential diagnosis of pulmonary diseases make them indispensable instruments for intensivists [1]. Despite their common use, a few studies have raised concerns about potential impacts on bronchoalveolar lavage fluid (BALF) dilution, which affects mainly the quantitative detection of soluble substances. Urea is a diffusible substance that can easily be detected in capillaries and alveolar spaces. The urea concentration in plasma and that in BALF are approximately equal and their ratio (urea plasma/urea BALF) has previously been applied as an index of BALF dilution. Furthermore, it has been shown that the ratio of high-quality lavage is low in clinical settings [2, 3].
We reviewed all ICU-admitted patients who received BAL from January 2016 to September 2018 in Ren Ji Hospital and analyzed their urea plasma/urea BALF values. Guidelines of the American Thoracic Society were followed during the BAL procedure [3]. (The procedure is described in Additional file 1.) Among 223 patients included, the median level of urea plasma/urea BALF was 4.2 (interquartile range of 3.2–8.6). The patients were categorized into groups A (urea plasma/urea BALF <4.2) and B (urea plasma/urea BALF ≥4.2). The patients in group A were more likely to receive bronchodilators (35.6% versus 15.9%, P <0.001) and a recruitment maneuver (15.5% versus 5.3%, P = 0.013) than those in group B. More invasive pulmonary aspergillosis (IPA) patients with BALF galactomannan of more than 0.5 could be detected in group A than in group B (84.6% versus 33.3%, respectively; P = 0.019) as well as more bacterial pneumonia patients with the quantitative cultures of BALF of more than 104 CFU/mL (90.6% versus 52.7%, respectively; P <0.001). Primary care physicians performed more BAL than residents did (58.3% versus 31.8%, respectively), especially in group A (Table 1).
Table 1
Demographics and clinical characteristics of the patients
Characteristics
All patients
Group A
(urea plasma/urea BALF <4.2)
Group B
(urea plasma/urea BALF ≥4.2)
P value
n = 223
n = 110
n = 113
Age, years
54 (43–67)
51 (43–66)
56 (43–67)
0.945
Gender, male
103 (46.2)
53 (48.2)
50 (44.2)
0.556
BMI, kg/m2
21.9 (18.5–23.4)
22.1 (18.4–23.4)
21.8 (18.5–23.4)
0.515
PaO2/FiO2
210.4 (120.4–271.5)
250.9 (206.7–320.5)
137.4 (88.6–210.4)
<0.001
Pulmonary disease
 AECOPD
68 (30.5)
33 (30.0)
35 (30.9)
0.875
 CAP
61 (27.4)
28 (25.5)
35 (30.9)
0.36
 HAP
33 (14.8)
17 (15.5)
14 (12.4)
0.508
 VAP
16 (7.2)
7 (6.4)
9 (7.9)
0.643
 IPA
28 (12.6)
13 (11.8)
15 (13.3)
0.743
 Others
17 (7.5)
12 (9.0)
5 (4.6)
0.068
APACHE II score
17 (13–23)
16 (14–22)
17 (13–23)
0.799
Intubation and mechanical ventilation
47 (21.1)
21 (19.1)
26 (23.0)
0.473
Lesion location
 Upper lobe
56 (25.1)
26 (23.6)
30 (26.5)
0.616
 Middle and lower lobe
93 (41.7)
51 (46.4)
42 (37.2)
0.164
 Diffusive lesions
74 (33.2)
33 (30.3)
41 (36.3)
0.319
Sedative and narcotic drugs
 Midazolam and fentanyl
96 (43.0)
51 (46.4)
45 (39.8)
0.324
 Propofol and fentanyl
89 (39.9)
42 (38.2)
47 (41.6)
0.603
 Dexmedetomidine
38 (17.1)
17 (15.4)
21 (18.6)
0.534
Bronchodilators was given before BAL
57 (25.6)
39 (35.6)
18 (15.9)
<0.001
RM before BAL
23 (10.3)
17 (15.5)
6 (5.3)
0.013
Operator
 Resident
71 (31.8)
5 (4.5)
66 (58.4)
<0.001
 Primary care physician
130 (58.3)
93 (84.5)
37 (32.7)
<0.001
 Others
22 (9.9)
12 (11.0)
10 (8.9)
0.616
Diagnosed with bacterial pneumonia
178 (79.8)
85 (77.3)
93 (82.3)
0.348
BALF GM >0.5 in IPA patients
16 (57.1)
11 (84.6)
5 (33.3)
0.019
Quantitative cultures of BALF >104 CFU/mL in bacterial pneumonia patients
126 (70.8)
77 (90.6)
49 (52.7)
<0.001
Data are expressed as median (Q1–Q3) or number (percentage). P values for comparison between urea plasma/urea BALF ≥4.2 and <4.2 groups.
Abbreviations: AECOPD acute exacerbation of chronic obstructive pulmonary disease, APACHE II Acute Physiology and Chronic Health Evaluation II, BAL bronchoalveolar lavage, BALF bronchoalveolar lavage fluid, BMI body mass index, CAP community-acquired pneumonia, CFU colony-forming units, FiO2 fractional concentration of inspired oxygen, GM galactomannan, HAP hospital acquired pneumonia, IPA invasive pulmonary aspergillosis, PaO2 partial pressure of arterial oxygen, RM recruitment maneuver, VAP ventilator-associated pneumonia.
Pulmonary function was associated with the urea plasma/urea BALF ratio. It was found that there was a correlation between urea plasma/urea BALF and partial pressure of arterial oxygen/fractional concentration of inspired oxygen (PaO2/FiO2) (R2 = 0.196, P <0.001). The less oxygen-deficient the patient was, the lower the urea plasma/urea BALF level was (Fig. 1a,b). Sixty-eight patients with chronic obstructive pulmonary disease (COPD) were enrolled in our study. The forced expiratory volume in the first second (FEV1) was suggested as a measure of bronchial obstruction. FEV1 of less than 50% of the predicted normal value indicated the presence of severe ventilatory impairment, which led to a lower volume of instilled saline flow into the alveoli. In our study, a correlation was also found between FEV1 and urea plasma/urea BALF (R2 = 0.299, P <0.001). A lower value of urea plasma/urea BALF was obtained in a group with FEV1 of at least 50% of the predicted value than in that with FEV1 of less than 50% of the predicted value (P <0.05, Fig. 1c, d).
Providing appropriate training in BAL skills to intensivists while ensuring patient safety is challenging [4]. Inter-operator variability in the recovery of lavage fluid during a BAL procedure may affect the concentration of soluble substances such as galactomannan and the results of quantitative cultures [5]. More attention should be paid to patients with hypoxia and impaired pulmonary function. Bronchodilators and a recruitment maneuver may improve BALF dilution during the procedure, and residents in ICUs need more practice.

Acknowledgments

None.

Funding

This work was supported by the National Key Research and Development Program of China (2017YFC0909002) and the Scientific Research Project of Shanghai Municipal Health Bureau (201840006).

Availability of data and materials

Not applicable.
This study was approved by the ethics committee of Shanghai Jiao Tong University (2016-Clinical-Res-083), and written informed consent was obtained from either the patients or the next of kin.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Ergan B, Nava S. The use of bronchoscopy in critically ill patients: considerations and complications. Expert Rev Respir Med. 2018;12:651–63.CrossRef Ergan B, Nava S. The use of bronchoscopy in critically ill patients: considerations and complications. Expert Rev Respir Med. 2018;12:651–63.CrossRef
2.
Zurück zum Zitat Baughman RP. The uncertainties of bronchoalveolar lavage. Eur Respir J. 1997;10:1940–2.CrossRef Baughman RP. The uncertainties of bronchoalveolar lavage. Eur Respir J. 1997;10:1940–2.CrossRef
3.
Zurück zum Zitat Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–14.CrossRef Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–14.CrossRef
4.
Zurück zum Zitat Roux D, Reignier J, Thiery G, Boyer A, Hayon J, Souweine B, et al. Acquiring procedural skills in ICUs: a prospective multicenter study. Crit Care Med. 2014;42:886–95.CrossRef Roux D, Reignier J, Thiery G, Boyer A, Hayon J, Souweine B, et al. Acquiring procedural skills in ICUs: a prospective multicenter study. Crit Care Med. 2014;42:886–95.CrossRef
5.
Zurück zum Zitat Yu Y, Zhu C, Gao Y. Bronchoalveolar lavage fluid galactomannan as a diagnostic biomarker for IPA: still a long way to go. Crit Care. 2016;20:280.CrossRef Yu Y, Zhu C, Gao Y. Bronchoalveolar lavage fluid galactomannan as a diagnostic biomarker for IPA: still a long way to go. Crit Care. 2016;20:280.CrossRef
Metadaten
Titel
Bronchoalveolar lavage fluid dilution in ICU patients: what we should know and what we should do
verfasst von
Yuetian Yu
Chunyan Liu
Zhongheng Zhang
Hui Shen
Yujie Li
Liangjing Lu
Yuan Gao
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2019
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2300-x

Weitere Artikel der Ausgabe 1/2019

Critical Care 1/2019 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.